Martin Koller

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

Juha O. Rinne, David J. Brooks, Martin N. Rossor et al. · The Lancet Neurology · 2010 · 694 citations

Neurodegenerative Diseases, Ascending-dose Study, Alzheimer's Disease +10

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

Joseph Jankovic, Ira Goodman, Beth Safirstein et al. · JAMA Neurology · 2018 · 283 citations · Full text

Evaluation of smartphone‐based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial

Florian Lipsmeier, Kirsten I. Taylor, Timothy Kilchenmann et al. · Movement Disorders · 2018 · 259 citations · Full text

First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers

Dale B. Schenk, Martin Koller, Daniel Ness et al. · Movement Disorders · 2016 · 242 citations · Full text

A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials

John Harrison, Sonia L. Minassian, Lisa Jenkins et al. · Archives of Neurology · 2007 · 217 citations